AI Therapeutics Announces Initiation of a Phase II Clinical Trial of AIT-101 for Treatment of ALS
January 13, 2022 10:38 ET
|
AI Therapeutics, Inc.
GUILFORD, Conn., Jan. 13, 2022 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the initiation...